Truncated IGF-1 research protein · Fact sheet
IGF-1 DES
Also known as Des(1–3)IGF-I · Des IGF-1
IGF-1 DES is an IGF-1 variant missing its first three amino acids. Greater activity in laboratory or animal experiments has not established a human bodybuilding or recovery treatment.
What is IGF-1 DES?
Des(1–3) names the three-amino-acid truncation. Altered interaction with IGF-binding proteins can increase experimental potency.
A truncated analog is not interchangeable with intact IGF-1, LR3 IGF-1 or approved mecasermin.
Benefits & claims
Interest centers on muscle protein synthesis and growth signaling. Potency in an assay does not predict a useful or safe human clinical effect.
What the evidence supports
- DES increased growth measurements in a mouse model and nitrogen retention in diabetic rats.
- In the rat study, IGF peptides did not correct abnormal glucose loss in the way insulin did.
- Experimental potency does not establish a human amount, frequency or therapeutic advantage.
Research areas
- IGF signaling
- Protein synthesis in animal models
- Growth-factor binding
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for IGF-1 DES. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- Des(1–3) names the three-amino-acid truncation. Altered interaction with IGF-binding proteins can increase experimental potency.
Formulation differences
- A truncated analog is not interchangeable with intact IGF-1, LR3 IGF-1 or approved mecasermin.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Human pharmacokinetics and safety
- Selective muscle versus other tissue effects
- Meaningful human functional outcomes
Side effects & risks
- The mouse study found increases in several organ weights, illustrating that growth effects need not be limited to muscle.
- Human adverse-event rates, glucose effects and long-term tissue-growth consequences have not been established.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchPrimary studies in growth-hormone-deficient mice and diabetic rats measured growth and nitrogen balance. These disease models are not human athletic-performance trials.
Studies
Animal study of length and organ weights.
Nitrogen retention and protein synthesis; not a human regimen.
Ovarian-cell experiment comparing altered IGF binding.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
There is no FDA-approved IGF-1 DES treatment. The cited preclinical studies do not establish an approved growth or recovery use.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Human pharmacokinetics and safety
- Selective muscle versus other tissue effects
- Meaningful human functional outcomes
Summary
Experimental potency does not establish a human amount, frequency or therapeutic advantage.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.